September 6, 2017 / 11:38 AM / 18 days ago

BRIEF-Aeglea Bio Therapeutics doses 2 patients in repeat dose as part of clinical trial

Sept 6 (Reuters) - Aeglea Bio Therapeutics Inc

* Aeglea Bio Therapeutics doses two patients in repeat dose part of phase 1/2 clinical trial for the treatment of arginase 1 deficiency

* Aeglea Bio Therapeutics -‍dosed 2 adults in repeat dose part of phase 1/2 clinical trial of AEB1102 for treatment of patients with Arginase 1 Deficiency​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below